Aclara Reports Shrinking Revenues, R&D Expenses, Losses for Q4; Wins Pfizer as Customer | GenomeWeb

NEW YORK, Jan. 29 (GenomeWeb News) - Aclara BioSciences reported decreased revenues, losses, and R&D expenses for the fourth quarter of 2003 yesterday, and said it has won Pfizer as a customer for its eTag assay system.

 

The company's fourth quarter revenues fell to $653,000 from $752,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.